Atlas
Back to RCM
Strategic Advisor·RCM

Bill Rutherford

Board of Managers member (retired EVP & CFO of HCA Healthcare, oversaw Revenue Cycle Operations) at Ensemble Health Partners

Nashville, Tennessee, USA

BR
Why they matter

He ran finance and revenue cycle for the largest U.S. hospital operator for a decade and now governs Ensemble, offering unmatched buyer-and-operator perspective on healthcare RCM.

Background

Bill Rutherford spent 34 years at HCA Healthcare, serving as Executive Vice President and CFO from 2014 until his retirement on May 1, 2024, with oversight of Treasury, the Controller's Office, IT, Government Programs, Strategic Resource Group and Revenue Cycle Operations (Parallon). His earlier HCA career included CFO of the Eastern Group (~90 hospitals, ~$12B revenue) and CFO of the Outpatient Services Group, plus a stint as COO of Psychiatric Solutions. In February 2025 he joined the Board of Managers of Ensemble Health Partners, the nation's largest revenue cycle managed-services company.

Notable deals

  • 2025
    Appointed to Board of Managers of Ensemble Health Partners, the RCM managed-services leader overseeing $37B+ in annual net patient revenue
  • 2024
    Retired as EVP & CFO of HCA Healthcare after a decade in the role and 34 years with the company, succeeded by Mike Marks effective May 1
  • 2023
    As HCA EVP & CFO, held management responsibility for Parallon (HCA's revenue cycle arm), Treasury, Controller's Office, IT and Government Programs

Call-prep brief

Background

  • 34-year HCA Healthcare veteran; joined as staff auditor in 1986, rose to EVP & CFO (2014 to May 2024). Oversaw Treasury, Controller, IT, Government Programs, Strategic Resource Group and Revenue Cycle Operations, including Parallon, HCA's in-house RCM arm.
  • Earlier roles: CFO of the Eastern Group (~90 hospitals, ~$12B revenue), CFO of Outpatient Services Group; left HCA 2005-2008 as COO of Psychiatric Solutions.
  • Joined Ensemble Health Partners' Board of Managers in February 2025 (Berkshire Partners-backed; $37B+ net patient revenue under management).

Current focus / what they care about

  • Governance at Ensemble: client outcomes, net revenue improvement, and how RCM vendors prove ROI to health-system CFOs.
  • Payer-provider friction: denials, Medicare Advantage behavior, government reimbursement policy.
  • Disciplined margin management and technology (automation, AI) in the revenue cycle.

Potential sensitivities

  • He sits on Ensemble's board — avoid asking for anything competitively sensitive about Ensemble or its PE owners, and be clear about confidentiality boundaries.
  • Recently retired; likely selective about time commitments.

Questions to ask

  1. From a health-system CFO's seat, what actually determines whether RCM is kept in-house (Parallon model) versus outsourced end-to-end?
  2. Where do denials management and payer behavior create the most durable margin opportunity for RCM vendors over the next five years?
  3. Which RCM technology claims (AI coding, autonomous prior auth) does he view as real versus overhyped, and how should a buyer diligence them?

Outreach draft

Subject
RCM diligence — your operator perspective
Dear Mr. Rutherford, We're a private equity deal team evaluating opportunities in healthcare revenue cycle management, and few people have seen the space from as many angles as you have — a decade as HCA's CFO with oversight of Parallon, and now on Ensemble's Board of Managers. We'd value 30 minutes of your perspective on how health-system CFOs weigh in-house versus outsourced revenue cycle, and where technology is genuinely changing the economics. We're happy to work around your schedule and to compensate you for your time through our expert network. Would a brief call in the coming weeks be possible? Best regards, [Your Name]

Linked companies

Sources